Strong franc hurts Roche but cancer drugs fight back
This article was originally published in Scrip
Executive Summary
In the first of the big pharma first-quarter earnings announcements, Roche has reported that its pharma sales have climbed 4% at constant exchange rates (-1% in Swiss francs) with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for the expected decline in Xeloda sales.